<DOC>
	<DOCNO>NCT00006168</DOCNO>
	<brief_summary>The major thrust determine whether treatment patient Primary Biliary Cirrhosis ( PBC ) Ursodiol ( Ursodeoxycholic Acid-UDCA ) plus methotrexate ( MTX ) effective treatment UDCA alone .</brief_summary>
	<brief_title>Ursodiol-Methotrexate Primary Biliary Cirrhosis</brief_title>
	<detailed_description>PBC chronic cholestatic liver disease , predominantly woman , interlobular septal bile ducts undergo inflammation destruction . Once initiate , disease persist progress vary rate . Neither initiate perpetuate mechanism well understood . Current concept pathogenesis include ( 1 ) destruction bile duct maintain perhaps initiate autoimmune mechanism ; ( 2 ) hydrophobic bile acid accumulate serum liver cause functional cytotoxic liver injury ; ( 3 ) cytokine lymphokine release site inflammation may contribute cell damage fibrosis . A considerable body evidence indicate UDCA feed orally lead improvement liver test , pruritus liver histology . There exist difference opinion whether development complication liver disease , liver transplantation transplant-free survival affect . UDCA , relatively non-toxic bile acid , administer orally , alters composition bile acid pool factor enrichment UDCA appear protect cytotoxic effect endogenous bile acid accumulate result bile acid destruction . MTX show improve liver test , symptom liver histology small number precirrhotic patient PBC . The mechanism action unknown felt related anti-inflammatory immunosuppressive effect MTX . The current trial explore whether MTX improve therapeutic effect UDCA PBC . Patients PBC whose serum bilirubin le 3 mg % , UDCA least 6 month , satisfy series inclusion exclusion criterion stratify 2 group basis liver histologic stage ( Ludwig classification ) , i.e. , early ( Stages I II ) versus late ( Stages III IV ) . They randomize receive either methotrexate placebo second drug continue receive UDCA . The relative value two treatment arm assess compare effect symptom , result laboratory test , development complication liver disease , histologic change liver , liver transplantation , transplant-free survival . The safety therapeutic regimen also determine .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Chronic cholestatic liver disease least 6 month ' duration . Serum alkaline phosphatase level least 1.5 time upper limit normal prior treatment UDCA . Serum bilirubin less 3.0 mg % prior treatment UDCA . Serum albumin 3.0 gram % great prior treatment UDCA . Positive antimitochondrial antibody test Liver biopsy within previous 6 month least 6 month UDCA ( available review , least 2 cm long cirrhosis detect ) compatible diagnosis PBC . Ultrasound , compute tomography ( CT ) cholangiography biliary tree excludes biliary obstruction . Treatment immunosuppressive agent include azathioprine , chlorambucil , colchicine , corticosteroid , dpenicillamine precede 3 month ; cyclosporine , FK506 methotrexate precede 6 month . Treatment rifampin precede 3 month . Serum bilirubin 3.0 mg % great . Serum albumin less 3.0 gm % . WBC 2,500 mm3 ; granulocytes 1,500 mm3 ; platelets 80,000mm3 . Ascites , hepatic encephalopathy , variceal bleed . Findings clinical , serologic histologic evidence liver disease etiology ( chronic hepatitis B C , autoimmune chronic active hepatitis , alcoholic liver disease , sclerosing cholangitis , druginduced liver disease , symptomatic obstructive gallstone ) . Pregnancy , pregnant reproductive period , unwillingness utilize adequate form birth control . Age le 20 great 69 year . Epilepsy require use dilantin . Malignant disease within past 5 year ( except skin cancer ) AntiHIV positive . Major illness could limit life span . History alcoholism previous 2 year . Creatinine clearance le 60 ml per minute . Severe lung disease , define diffusion capacity vital capacity le 50 percent predict . Patients asymptomatic Stage I histology liver biopsy ( Ludwig classification ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>primary biliary cirrhosis</keyword>
	<keyword>Ursodeoxycholic acid</keyword>
	<keyword>UDCA</keyword>
	<keyword>MTX</keyword>
	<keyword>Hepatology</keyword>
	<keyword>methotrexate</keyword>
	<keyword>liver</keyword>
</DOC>